Fate Therapeutics Shares Twist 37% Upward on Data from Two Phase 1 B-cell Lymphoma Trials
Source: Streetwise Reports  (12/7/20)
Fate Therapeutics shares set a new 52-week high after the firm reported positive interim data from its Phase 1 Study of FT516 in combination with rituximab for B-cell lymphoma. In a separate Phase 1 study, the company presented the results of a patient treated with natural killer cell cancer immunotherapy FT596 in refractory diffuse large B-cell lymphoma. More >

Biotech's Potentially Disruptive Diagnostics Platform on 'Cusp of Commercialization'
Source: Streetwise Reports  (12/6/20)
Recent trial results, a timeline to the launch of Quotient's system and the reasons the debut should be successful are discussed in a Cowen report. More >

BioCryst Awarded FDA Approval for Medicine Preventing Attacks in HAE Patients
Source: Streetwise Reports  (12/4/20)
BioCryst Pharmaceuticals shares traded 17% higher after the company reported that the FDA approved its once-daily oral therapy ORLADEYOâ„¢ (berotralstat) for prevention of attacks in hereditary angioedema patients. More >

Oramed Pharma Shares Gain 11% as Firm Initiates Phase 2 NASH Trial of Oral Insulin
Source: Streetwise Reports  (12/3/20)
Shares of Oramed Pharmaceuticals traded higher after the company announced that it has initiated a Phase 2 NASH trial of oral insulin as a complementary agent or alternative to insulin injections. More >

Biotech Licenses Platform for Faster Pathway for Cancer and COVID-19 Vaccine Trials
Source: Streetwise Reports  (12/2/20)
The rationale behind OncoSec Medical using this system is discussed in a Dawson James report. More >

Patterson Company's Shares Gain 13% on Q2 Earnings and 9.5% YoY Sales Growth
Source: Streetwise Reports  (12/2/20)
Patterson Companies shares traded higher and set a new 52-week high after the firm reported Q2/21 financial results which included a 12.1% YoY increase in dental equipment and consumable supply sales. More >

Novavax Shares Get a Boost from Developments at Three Separate COVID-19 Vaccine Trials
Source: Streetwise Reports  (11/30/20)
Novavax shares traded 11% higher after the company finalized enrollment in two advanced COVID-19 vaccine clinical trials with a third one slated to commence in the coming weeks. More >

Rhythm Pharma Earns FDA Approval for Chronic Weight Management Drug for Rare Genetic Obesity Diseases
Source: Streetwise Reports  (11/27/20)
Shares of Rhythm Pharmaceuticals traded 25% higher after the FDA granted approval of IMCIVREEâ„¢ (setmelanotide) as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency. More >

Pharma Developer Raises Enrollment Goal for Multinational Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (11/25/20)
Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition. More >

Biopharma Targeting Glioblastoma Multiforme Commences Clinical Program
Source: Streetwise Reports  (11/25/20)
Preclinical results for Black Diamond Therapeutics' kinase inhibitor, BDTX-1535, are reviewed in an H.C. Wainwright & Co. report. More >

U.S. Biopharma Expands Into ALS, Doses First Patient in 'Potentially Pivotal' Trial
Source: Streetwise Reports  (11/25/20)
The design of Apellis Pharmaceuticals and its partner's clinical study is presented in a ROTH Capital Partners report. More >

Renalytix AI Shares Climb 30% on Q1 Earnings and EUA for JV's SARS-CoV-2 IgG Antibody Test Kit
Source: Streetwise Reports  (11/25/20)
Shares of Renalytix AI Plc. traded 30% higher after the company reported Q1/21 financial results and that its joint venture with Mt. Sinai Health System was granted Emergency Use Authorization by the FDA for its SARS-CoV-2 IgG antibody test kit. More >

Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications
Source: Streetwise Reports  (11/23/20)
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm. More >

Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders
Source: Streetwise Reports  (11/20/20)
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets. More >

Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling
Source: Streetwise Reports  (11/19/20)
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid. More >

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering
Source: Streetwise Reports  (11/18/20)
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration. More >

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies
Source: Streetwise Reports  (11/17/20)
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits. More >

Psychedelic Company Expected to Begin Trading Nov. 18
Source: Streetwise Reports  (11/17/20)
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange. More >

Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy
Source: Streetwise Reports  (11/16/20)
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%. More >

Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin
Source: Streetwise Reports  (11/14/20)
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams. More >

Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer
Source: Streetwise Reports  (11/13/20)
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash. More >

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results
Source: Streetwise Reports  (11/12/20)
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus. More >

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug
Source: Streetwise Reports  (11/11/20)
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab. More >

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December
Source: Streetwise Reports  (11/11/20)
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020. More >

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic
Source: Streetwise Reports  (11/11/20)
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report. More >